ABSTRACT Liposomal drugs are a useful alternative to conventional drugs and hold great promise for targeted delivery in the treatment of many diseases. Most of the liposomal drugs on the market or under clinical trials include cholesterol as a membrane stabilizing agent. Here, we used liposomal CA4P, an antivascular drug, to demonstrate that cholesterol content can actually modulate the release and cytotoxicity of liposomal drugs in a delicate and predictable manner. We found that both the rate of the CA4P release from the interior aqueous compartment of the liposomes to the bulk aqueous phase and the extent of the drug's cytotoxicity undergo a biphasic variation, as large as 50%, with liposomal cholesterol content at the theoretically predicted C r , e.g., 22.0, 22.2, 25.0, 33.3, 40.0, and 50.0 mol % cholesterol for maximal superlattice formation. It appears that at C r , CA4P can be released from the liposomes more readily than at non-C r , probably due to the increased domain boundaries between superlattice and nonsuperlattice regions, which consequently results in increased cytotoxicity. The idea that the increased domain boundaries at C r would facilitate the escape of molecules from membranes was further supported by the data of dehydroergosterol transfer from liposomes to MbCD. These results together show that the functional importance of sterol superlattice formation in liposomes can be propagated to distal targeted cells and reveal a new, to our knowledge, mechanism for how sterol content and membrane lateral organization can control the release of entrapped or embedded molecules in membranes.
INTRODUCTION
During the past decade there has been an increasing interest in antivascular therapies that damage the existing tumor microvasculature and cause a rapid and extensive shutdown of tumor blood flow. The most prominent of these agents, CA4, is a tubulin binding drug that disrupts the formation of microtubules (1) , which are essential for intracellular protein trafficking, cell movement, and mitotic cell division. Disruption of microtubule formation by CA4 thus reduces cell proliferation and viability. CA4 preferentially binds tubulin in endothelial cells of tumor blood vessels (2) . As a result, CA4 induces a pronounced reduction in blood flow to solid tumors, leading to extensive tumor cell necrosis (2) (3) (4) .
CA4P is a prodrug of CA4. After administration, CA4P is rapidly cleaved to CA4 by endogenous phosphatases. CA4P is clinically more favorable than CA4 due to the significantly greater solubility of CA4P in water. CA4P induces vascular shutdown within tumors at doses less than onetenth of the maximum tolerated dose (2) . As with CA4, the antivascular effect of CA4P has been demonstrated both in animal models (5, 6) and human cancer patients (7, 8) . CA4P has been used in combination with conventional chemotherapy and radiotherapy against a range of tumor types, including breast cancer. An important limitation of combretastatin is that it also significantly alters blood flow in many normal tissues including heart, brain, spleen, skin, and kidney (9) . In the case of the brain and the heart, even minute changes in blood flow may cause serious harm to the patient.
In an attempt to reduce this potential side effect and increase blood retention time of the drug, we have recently employed liposomal CA4P in animal studies (10, 11) . The advantages of using liposomal drugs as opposed to free drugs are well documented in the literature (12, 13) and include the ability to selectively deliver liposomes to the desired site in the body. Our previous study showed that targeting anti-E-selectin conjugated immunoliposomes loaded with CA4P to MCa-4 mammary tumors in mice treated with therapeutic doses of ionizing radiation resulted in a significant delay in tumor growth when compared with other treatment groups such as free CA4P, tumor irradiation alone, liposomal CA4P alone, and empty liposomes (10) . In this study, radiation was used to upregulate expression of endothelial cell adhesion molecules (e.g., E-selectin), which provided a means for targeting drugs to irradiated tissue. Although this approach is very promising, the overall efficacy of the liposomal CA4P was limited. Our data showed that the combination treatment with ionizing radiation and immunoliposomes still allowed tumors to increase in size over time, although the rate was reduced significantly (10) .
One conceivable method to improve this efficacy problem is to optimize the liposomal formulation. In our previous study (10) , we used unilamellar vesicles composed of hydrogenated soy phosphatidylcholine, cholesterol, and distearoyl-L-a-phosphatidylethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt) (molar ratio: 50:45:5). In this formulation, as in many other liposomal anticancer drugs, cholesterol was used as a membrane stabilizing agent, but the cholesterol content (45 mol %) of the liposome was chosen somewhat arbitrarily.
Many studies of cholesterol in liposomes have revealed that cholesterol content in membranes is not a trivial issue. In fact, cholesterol content is a critical factor involved in the regulation of membrane properties. Specifically, it has been established that cholesterol content affects physical and biochemical properties of liposomal membranes in a nonmonotonic manner (reviewed in (14) (15) (16) ). Many membrane properties display a biphasic change at the C r , at which the extent of sterol superlattice in the plane of the membrane reaches a local maximum (reviewed in (14, 15) (21) . Prominent examples of multiple biphasic changes in membrane properties at these C r values include the activities of phospholipase A2 (22) , cholesterol oxidase (23, 24) , and Na,K-ATPase (25, 26) as well as the partitioning of the antifungal drug nystatin (27) , the rate of free radical-induced sterol oxidation (28) and the interactions of b-amyloid peptide with lipid membranes (29) . It is then logical to hypothesize that cholesterol content in liposomal formulations could also affect the drug's actions and overall efficacies in a multiple biphasic manner in accordance with the physical principles of sterol superlattice formation (17, 21) .
In this study, we examined the effect of cholesterol content in liposomal CA4P formulations on the drug's action on MCF-7 breast cancer cells. We employed a rather unconventional approach, using small cholesterol mole fraction increments (0.5 mol %) over a wide cholesterol mole fraction range. Our findings indicate that both the rate of the drug release from the interior aqueous compartment of the liposomes to the bulk aqueous phase and the extent of the drug's cytotoxicity fluctuate with liposomal cholesterol content. This variation is observed as a biphasic change at C r , fully in accordance with the physical principles of sterol superlattice formation. It appears that at C r , CA4P can be released from the liposomes more readily than at non-C r , probably due to the increased domain boundaries between superlattice and nonsuperlattice regions, resulting in increased cytotoxicity. This explanation is supported by an independent experiment that monitored the initial rate of sterol transfer from liposomes to MbCD, a water-soluble macrocyclic molecule able to attract membrane sterols to its hydrophobic cavity. Our data reveal a new, to our knowledge, mechanism for how sterol content and membrane sterol lateral organization can control the release of entrapped or embedded molecules in membranes. These results strongly suggest that cholesterol content should be carefully considered in the context of sterol superlattice formation when designing liposomal drugs for therapeutic treatment of cancer and other conditions.
MATERIALS AND METHODS

MCF-7 cell line
Human MCF-7 breast cancer cells (American Type Culture Collection, Manassas,VA) were grown at 37 C with 5% CO 2 atmosphere using complete growth medium composed of Dulbecco's modified Eagle's medium (1Â, with 4.5g/L glucose, L-glutamine, and sodium pyruvate) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. When~80% confluency was reached, cells were detached using 0.25% trypsin-EDTA, rinsed with phosphate-buffered saline, and collected after centrifugation at 2000 Â g for 5 min at 25 C. Cells were then resuspended into complete growth medium, plated into a 96-well microplate (~10,000 cells per well) and maintained in a serum-containing medium for >12 h, until the cells adhered to the wall of the microplate wells.
Preparation of liposomal CA4P
CA4P-entrapped liposomes composed of cholesterol and POPC (Avanti Polar Lipids, Alabaster, AL) were prepared. Calculated amounts of POPC and cholesterol in chloroform were pipetted into test tubes and dried under N 2 until no visually detected solvent remained, and then further dried overnight under high vacuum. The lipids were then reconstituted with 5.0 mL of 50 mM Tris-HCl buffer (pH 7.2) containing 30 mM CA4P (synthesized as described in (10)), 0.02% NaN 3 , and 10 mM EDTA at 40 C, flushed with N 2 and vortexed for 3 min at 40 C to form MLVs. The MLVs were cooled to 4 C for 30 min and then incubated at 40 C for 30 min. After being exposed to three cycles of heating/cooling to allow for thorough mixing, vesicles were incubated for 4 days at room temperature to achieve thermal equilibrium. During incubation, liposome samples were protected from light and heat, flushed with argon gas, and sealed with Teflon-lined screw caps to prevent lipid and drug autooxidation (30) .
Several sample sets of CA4P-entrapped cholesterol/POPC MLVs were prepared. Every sample within the set contained the same absolute amount of cholesterol, varying only in the cholesterol mole percent. This was accomplished by varying the number of moles of POPC per tube while leaving the number of moles of cholesterol constant. Cholesterol mole percent was changed by 0.5 mol % for each sample. These sample sets together cover the cholesterol mole fractions 18-52 mol %. In this range LUVs. The LUV samples were then stored under argon at room temperature for R7 days before the cytotoxicity assay and drug release measurements.
The diameter of the extruded LUVs was~180 nm as measured by photon correlation spectroscopy using the Malvern Zetasizer HS-1000 spectrometer (Worcestershire, UK). Our previous study (27) showed that the sterol mole percents in vesicles before and after extrusion differ little (%0.2 mol %). Thus, for convenience, the cholesterol mole percents in MLVs were used to assess the relationship between liposomal cholesterol content and drug release as well as the drug's cytotoxicity in MCF-7 breast cancer cells. The experimental errors for the cholesterol mole fractions have been previously determined (using photometric and cholesterol oxidase assays) to be 0.1-0.4 mol % (23,31).
Separation of free CA4P from liposomal CA4P
Immediately before the cytotoxicity assay and the CA4P release experiment, free CA4P was removed by a Sephadex G-50 gel filtration column (8 Â 105 mm). The column was loaded with 100 mL of 1 mM liposomal lipids and eluted with 50 mM Tris-HCl buffer (pH 7.0) containing 10 mM EDTA. The elution profile was determined using light scattering and CA4P fluorescence intensity. The fractions containing liposomes with entrapped CA4P were pooled. The amount of CA4P in liposomes was determined by first extracting 600 mL of the pooled fractions with 2 mL of chloroform/methanol (2:1, v/v). The entrapped CA4P (which is water soluble) was released from liposomes and partitioned into the aqueous phase. The absorbance at 300 nm of the aqueous phase was then measured on a Perkin-Elmer lambda-25 spectrophotometer to determine the amount of CA4P entrapped in the liposomes. The extinction coefficient of CA4P in buffer (pH 7.0) at 300 nm is estimated to be 5640 M À1 cm À1 .
Cytotoxicity assay
After the MCF-7 cells were treated with liposomal CA4P for 90 min at 37 C, the dead cells (floating in the growth medium) were removed. The cell proliferation assay was performed to determine the number of cells remaining alive (defined as those still attached to the well). The assay was performed at room temperature (~24 C) using the CyQuant kit (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Fluorescence intensities at 530 nm were measured on a Spectra Max M5 microplate reader (Molecular Devices, Sunnyvale, CA) with excitation at 485 nm. A standard curve was constructed for each sample set using known amounts of MCF-7 cells counted with a hemacytometer so that the fluorescence intensities could be converted to the cell numbers. Typically, 0.5 nmole of CA4P in liposomes was added to each of the 96-wells in the microplate, which had~10,000 cells per well at time zero. The maximum volume of liposomal CA4P added to the well was 50 mL and the total volume (growth medium plus vesicle dispersions in buffer) in each well was 200 mL.
Release of entrapped CA4P from liposomes
At the concentration used in the liposomal CA4P preparation (30 mM), the entrapped CA4P is in a self-quenched state. Leakage of entrapped CA4P from liposomes was monitored by measuring the increase of CA4P fluorescence intensity due to the relief of self-quenching. Specifically, 200 mL of liposomal CA4P dispersions collected from Sephadex G-50 (described above) was mixed with 2 mL of 50 mM Tris buffer (pH 7.2) containing 10 mM EDTA and 0.02% NaN 3 . The samples were excited at 328 nm, and the fluorescence intensity at 400 nm (F t ) was recorded as a function of time on an ISS K2 fluorometer (Champaign, IL). At the end of each leakage experiment, the sample was mixed with the detergent n-tetradecyl-b-Dmaltoside (Anatrace, Maumee, OH) (final concentration in the cuvette ¼ 100 mM) for 20 min to release all the entrapped CA4P, providing the maximal fluorescence intensity (F max ). The equation
, where k is the rate constant of leakage, t is time, and A and B are constants, was used to fit the normalized fluorescence intensity (F ¼ F t /F max ). For each cholesterol mole fraction examined, the leakage assay was repeated six times. At C r , three independently prepared samples were tested to assess reproducibility. The initial rate (R ¼ dF/dt(at t ¼ 0) ¼ kB) of CA4P leakage was defined as the first derivative of F at time zero. Time zero is the time at which fluorescence measurement was begun, i.e., 10 s after the samples exited the Sephadex column. Because this deadtime (10 s) was the same for every sample, comparing the R values among different samples is meaningful. R is expressed as the change in normalized fluorescence intensity (DF) per second.
Release of sterol from liposomes to MbCD
A further experiment was conducted to test whether the biophysical principle governing release kinetics in the CA4P leakage assay can be applied to other molecules entrapped in liposomes. Here, we examined the sterol transfer from liposomes to MbCD, a water-soluble macrocyclic compound able to take up sterols from membranes. LUVs composed of POPC, DHE, and Dansyl-PE (Avanti Polar Lipids) were examined. DHE (HPLC purified Sigma, St. Louis, MO) was used as a fluorescent cholesterol analog and, simultaneously, as a membrane component. DHE content was varied in steps of 0.4 mol % in the range 18-52 mol %. The molar ratio of DHE/Dansyl-PE was kept constant (15:2) in all samples. The buffer used in this experiment was 50 mM Tris containing 10 mM EDTA and 0.02% NaN 3 at pH 7.2. To trigger the DHE transfer reaction, 40 mL of 600 mM MbCD (in buffer) was added to liposome dispersions containing 12 nmol of DHE. The final volume of the reaction mixture was 1.6 mL. The rate of sterol transfer was monitored at room temperature (~24 C) based on the fluorescence resonance energy transfer between DHE (donor) and Dansyl-PE (acceptor) (32) . When DHE is transferred from LUVs to MbCD, energy transfer efficiency is decreased and, consequently, the fluorescence intensity of Dansyl-PE (monitored at 500 nm on the ISS K2 fluorometer using l ex ¼ 300 nm) decreases over time. The initial rate of the fluorescence intensity decrease (inferentially, the initial rate of DHE transfer) was determined by a single exponential fit of the data and by evaluating the first derivative of the fitted function at time zero.
RESULTS AND DISCUSSION
Effect of cholesterol content in liposomal CA4P on MCF-7 cytotoxicity First, we used the CyQuant kit to demonstrate that although liposomal CA4P can cause cytotoxicity in MCF-7 human breast cancer cells, empty liposomes are not toxic to these cells. Fig. 1 shows that liposomal CA4P (triangles) induced a significant decrease in the number of live cells relative to untreated cells (squares), especially during the first 90 min. In contrast, treatment with liposomes alone (circles, Fig. 1 ) did not result in any decrease in cell number. These data indicate that the decrease in the number of live cells induced by liposomal CA4P (triangles, Fig. 1 ) can only be attributed to the microtubule disruptive effect of CA4P leading to cell function shutdown, rather than the liposomes per se.
We then used the CyQuant kit to study the effect of cholesterol content in liposomes on the CA4P-engendered cytotoxicity in MCF-7 breast cancer cells. Five sample sets of liposomes with different cholesterol mole percents were examined (Fig. 2) . In each sample set, the number of cells and the amount of liposomal CA4P added to the cells Biophysical Journal 102(9) 2086-2094 in each microplate well at time zero were fixed (see Materials and Methods). Fig. 2 shows that the percentage of MCF-7 cells remaining alive in the microplate wells after treatment with liposomal CA4P for 90 min depends on liposomal cholesterol content. Remarkably, the cytotoxicity of liposomal CA4P against MCF-7 cells varies significantly (as large as 50% change in cytotoxicity) with liposomal cholesterol content in a well-defined alternating manner (Fig. 2) . The cytotoxicity, which is inversely proportional to the number of live cells remaining in the microplate well, is maximal when the cholesterol content in the liposomes is at 20.0, 22.2, 25.0, 26.0, 33.3, 40.0, and 50 mol % (designated as C s,min , Fig. 2) . C s,min is defined as the cholesterol mole fractions where the cell survival is minimal (i.e., cytotoxicity is maximal). All these C Fig. 2) .
Effect of cholesterol content on the release of CA4P from liposomes
To gain a mechanistic understanding of the results shown in Fig. 2 , we have used the intrinsic fluorescence of CA4P to develop an assay to monitor the spontaneous release of entrapped CA4P from the liposomes (see Materials and Methods). As illustrated in Fig. 3 , the release of entrapped CA4P results in fluorescence intensity enhancement due to the relief of self-quenching. More importantly, Fig. 3 shows that the initial rate of the fluorescence intensity change at C r (e.g., 40 .0 mol %) is much faster than that from the liposomes at the neighboring non-C r (e.g., 41 .0 and 39.5 mol %). R is expressed as the change in normalized fluorescence intensity (DF) per second. The initial rate of the drug release (R) can be expressed as the change in normalized fluorescence intensity (DF) per second (see Materials and Methods). To directly compare CA4P release data with the cytotoxicity data, which were obtained at 37 C, some of the drug release experiments were conducted at 37 C. The results are presented in Fig. 4 , where two sample sets covering two theoretical C r values (33.3 and 40.0 mol %) was examined. In this figure, local maxima in R are seen at 33.3 and 40.5 mol % cholesterol, which are in good agreement with the theoretical C r values. The drug release experiment at 37 C has a minor technical problem. That is, the liposomal drug isolated from the Sephadex G-50 column (water jacketed at 37 C) was exposed to room temperature briefly (10 s) before the fluorescence measurements (at 37 C). To demonstrate that this brief temperature perturbation does not lead to any significant changes to our conclusion, we did the drug release experiment at room temperature (24 C) as well (Fig. 5) . We found that, at 24 C, the initial rate of CA4P release varies with cholesterol content in an alternating manner, showing local maxima at 20. Our previous experiments (23, 33) showed that biphasic changes in membrane properties at C r would occur as long as the membrane was above the gel-to-liquid crystalline phase transition temperature of the matrix lipids and below~60 C, where thermal-induced randomization would dominate. Statistical mechanical calculations also showed that the lower mole fraction limit where the calculated phase boundary begins to deviate from the measured phase boundary decreases with decreasing temperature (21) . For cholesterol/DMPC mixtures, those lower limits are 16.7 mol % at 45 C and 8 mol % at 35 C (21). Conceivably, the lower mole fraction limit for sterol superlattice formation at 24 C would be much lower (<8 mol %) than the mole fractions examined in this study (18-52 mol %). Hence, the selection of 24 C is justified in two aspects. First, this method avoids any temperature perturbation to the membrane during the drug release experiment; second, it maintains the membrane in a physical state that is expected to sustain sterol superlattice formation. Because the 24 C (room temperature) experiment is more convenient, we obtained more data points and covered a wider mole fraction range for 24 C than for 37 C. However, the final conclusion is the same, that is, that R is maximal at or near C r .
A biphasic change at 26 mol % cholesterol was observed in the cytotoxicity measurements (Fig. 2) but not in drug release (Figs. 4 and 5) . As mentioned earlier, 26 mol % is not one of the predicted critical mole fractions for maximal superlattice formation. We speculated that the dip in cell survival rate at 26 mol % (Fig. 2) may come from the coexistence of two different sterol superlattices with two different compositions, for example, 25.0 and 33.3 mol %, as discussed previously (22, 30, 31) . In our previous studies of sterol superlattices, the dips or peaks in membrane properties or membrane-mediated processes at~26 mol % were observed only in rare cases (22, 30, 31) . In contrast, the dips/peaks at 20.0, 22.2, 25.0, 33.3, 40.0, and 50.0 were observed every time. Thus, the lateral structure corresponding to 26 mol % is likely to be metastable. The metastability may explain why a biphasic change at 26 mol % appeared in one assay but not in the other experiment. 
Data interpretation via the sterol superlattice model
The biphasic change in the initial rate of CA4P release at C r can be explained using either the conventional sterol superlattice model (14, 15, 17) or the recently proposed sludge model (21) . The conventional sterol superlattice model proposes that cholesterol can be organized in a regular lattice within the matrix lattice formed by lipid acyl chains and sterol molecules. The sludge model proposes that a rigid cluster is formed by a cholesterol molecule and phospholipid molecules that are condensed to the cholesterol. Rigid clusters of similar size tend to form aggregates, in which cholesterol molecules are regularly distributed into superlattices. Both models contend that, at any given cholesterol mole fraction, sterol superlattice (regular) regions always coexist with nonsuperlattice (irregular) regions (14, 17, 21, 34) . However, at the C r , the ratio of superlattice/ nonsuperlattice domains reaches a local maximum (14, 17, 21, 30) (21) .
At C r there should be a large increase in the interfacial area between the regular and irregular regions. This point can be understood as follows. First, there is a sharp biphasic change (reaching a maximum) in the area covered by superlattices (A reg ) at C r as calculated by either a statistical mechanical model of cholesterol and phospholipids or by using the nystatin partition coefficient (21, 23, 27) . Second, using statistical thermodynamics, we have calculated the cooperativity energy of superlattice lattice formation (u) at each of the critical sterol mole fractions examined in this study (21) . All the u values at C r (325.9 cal/mol for 20.0 mol %; 319.2 cal/mol for 22.2 mol %, 312.4 cal/mol for 25.0 mol %, 297.8 cal/mol for 33.3 mol %, 289.6 cal/mol for 40.0 mol %; 280.1 cal/mol for 50.0 mol %) are smaller than the thermal energy unit, kT (21) . Because of the small u values, there should be numerous aggregates (rather than a single large domain) of rigid clusters (superlattices) with a broad size distribution at C r , according to the work of Sugar (35) . Taken together, the perimeter of the regular region (thus, the interfacial area between the regular and irregular regions) must reach a local maximum at C r as previously proposed (30) .
Compared to other regions in the membrane, the interfacial areas between regular (superlattice) and irregular (nonsuperlattice) domains should be more defective, possessing more void space and volume fluctuations. Membrane defects or volume fluctuations could promote solute permeation (36) and channel formation (37) . Hence, the spontaneous release of CA4P through the domain interfacial regions should be faster than through other regions of the membranes. This concept is schematically described in Fig. 6 . Because the interfacial regions between superlattices and nonsuperlattices are maximal at C r (30) , the rate of CA4P leakage is faster at C r than that at the neighboring non-C r , thus producing a biphasic change in R at C r (Figs.  3-5 ). As such, our CA4P release data (Figs. 3-5 ) can be satisfactorily explained by the sterol superlattice models.
Because the release of the entrapped CA4P from liposomes into the aqueous phase is faster at C r , liposomal CA4P exhibits a more pronounced cytotoxic effect on MCF-7 cells at C r than at the neighboring non-C r (Fig. 2) . In each of the samples within the same sample set for the cytotoxicity experiment, the cell number at time zero (e.g., 10,000) and the amount of liposomal CA4P added (e.g., 0.5 nmole CA4P) were fixed. According to the conventional wisdom, one would predict the same cell survival rate for all the samples examined. However, our data ( Fig. 2) show that this is not the case. Here, we demonstrate that the cell survival rate varies by as much as 50% with the cholesterol content of the liposomal drug in a biphasic manner, reaching a local minimum at C r (Fig. 2) . These results are worth noting and can be best interpreted by the concept of sterol superlattice formation.
Release of DHE from liposomes to MbCD
In addition to CA4P, other molecules that are entrapped could also escape from liposomes more easily at C r than at non-C r , because at C r the interfacial regions between FIGURE 6 Schematic drawing illustrating the concept that the rate of spontaneous release of entrapped CA4P varies with the lipid packing maintained in different membrane regions. In a cholesterol-containing lipid membrane, superlattice and nonsuperlattice regions always coexist (17) . The interfacial areas between superlattice and nonsuperlattice domains are more defective, possessing more void space and volume fluctuations. Hence, the spontaneous release of CA4P through the interfacial regions is faster than through other regions of the membranes.
Biophysical Journal 102 (9) (Fig. 7) show that the rate of DHE transfer from DHE/ POPC/Dansyl-PE LUVs to MbCD is governed by the extent of sterol superlattice in the liposomal membrane, a conclusion similar to that obtained from the CA4P release experiment (Figs. 4 and 5 ). Note that, upon addition of MbCD to trigger sterol transfer, the membrane lateral organization is perturbed; thus, we only determined the initial rate of sterol transfer so that we could link the transfer data to membrane lateral organization. Furthermore, note that in the measurements of CA4P release and cytotoxicity (Figs. 2, 4 , and 5) we did not scan the concentration range around 28.6 mol %, an additional critical sterol mole fraction for maximal superlattice formation predicted by the newly proposed sludge model (21) .
Biophysical and pharmaceutical implications
This study demonstrates that the functional importance of cholesterol superlattice in liposomes can be manifested in targeted cells. Cholesterol lateral organization in the membrane is a long-standing conundrum that is of fundamental importance in understanding the role of cholesterol in membranes or cells. Considerable spectroscopic and functional evidence supporting the superlattice model has been reported in the literature (reviewed in (14, 20) ). For the functional evidence, we and others have previously reported that the activities of membrane surface acting enzymes and membrane-bound proteins, such as phospholipase A2 (22) , cholesterol oxidase (23) , and Na, K-ATPase (25) , as well as the rate of free radical-induced sterol oxidation (28, 39) and the partitioning of the antifungal drug nystatin into membranes (27) are regulated by the extent of sterol superlattice in the membrane. Here, we show that the release of entrapped CA4P and the cytotoxicity of liposomal CA4P against breast cancer cells are also regulated by the extent of sterol superlattice in the liposomes. These results provide the most compelling functional evidence for sterol superlattice formation and show that the functional importance of sterol superlattice formation in liposomes can be propagated to distal targeted cells.
This work is also highly significant from a pharmaceutical perspective. There is increasing evidence showing that liposomal drugs have significant advantages over free drugs for many therapeutic and prophylactic purposes (12, 13) . To date, >20 liposomal anticancer drugs are on the market or under clinical trials (40) (41) (42) . About 75% of them include cholesterol as a major component (40, 42) . Cholesterol has been used mainly because it can increase liposome stability in circulation and other tissues and because in some cases (43) it was required for the liposomal drug to exhibit strong antiproliferation activity toward tumor cells. Previous studies have shown that the amount of cholesterol in liposomal drugs is important. For example, a patent application for a doxorubicin liposomal formulation (U.S. patent 4898735) claimed that 20 mol % cholesterol caused a 2-3 times increase in drug retention, but no additional improvement was seen up to 50 mol % cholesterol. Another study showed that increasing cholesterol in the CA4 liposomal formulation decreased drug loading and drug leakage from the liposomes (44) . However, these studies used large cholesterol increments (10-30 mol %). When using large mole fraction increments, the actual cholesterol dependence of liposomal drug activity could elude detection or the result may lead to an erroneous conclusion as demonstrated in (30) . Furthermore, there is currently no rational, sciencebased method to select the optimal amount of cholesterol.
In this study, we demonstrate that cholesterol does not simply serve as a membrane stabilizing agent. By using small cholesterol mole fraction increments (0.5 mol %), we found that cholesterol content can actually modulate the release and the cytotoxicity of liposomal CA4P in accordance with the concept of sterol superlattice. Hence, the concept of sterol superlattice can be employed to optimize the cholesterol content in liposomal drug formulations to achieve higher efficacy for therapeutic treatment of cancer and other conditions. This approach has the potential to impact liposomal drug formulations already in use as well as to aid in predicting the most effective concentration of cholesterol in new formulations without time-consuming trial and error. Although our present data show maximal drug release and cytotoxicity at the C r for greatest superlattice formation, we cannot claim at this time that liposomal CA4P at C r is the best formulation for in vivo applications. Studies in animal models are the obvious next step, which will generate information on circulation times, biodistribution, and tumor-growth inhibition with liposomal formulations containing different mol % of cholesterol. If the time for liposomes to reach the target, i.e., tumors, is much shorter than the time for spontaneous drug release in the circulation, then there is a high possibility that liposomal CA4P is most effective in suppressing cancer cell growth when the liposomal cholesterol content is at C r due to increased cytotoxicity. On the other hand, if the time to reach the target is much longer than the time for spontaneous drug release, then it is likely that liposomal CA4P is least effective when the liposome cholesterol content is at C r . This predicted reduction in efficacy is due to leakage of the drug in areas other than the target region, leading to collateral damage to normal tissues. Nevertheless, our results reveal a new, to our knowledge, biophysical concept for designing liposomal drugs for cancer treatment. This strategy, when used in combination with radiation/chemotherapy and targeted delivery, may significantly increase the overall therapeutic efficacy of liposomal anticancer drugs.
